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Abstract
Aims/hypothesis Ageing can lead to reduced insulin sensitiv-
ity and loss of pancreatic beta cell function, predisposing
individuals to the development of diabetes. The aim of this
study was to assess the contribution of microRNAs (miRNAs)
to age-associated beta cell dysfunction.
Methods The global mRNA and miRNA profiles of 3- and
12-month-old rat islets were collected by microarray. The
functional impact of age-associated differences in miRNA
expression was investigated by mimicking the observed
changes in primary beta cells from young animals.
Results Beta cells from 12-month-old rats retained normal
insulin content and secretion, but failed to proliferate in re-
sponse to mitotic stimuli. The islets of these animals displayed
modifications at the level of several miRNAs, including upreg-
ulation of miR-34a, miR-124a and miR-383, and downregula-
tion of miR-130b andmiR-181a. Computational analysis of the
transcriptomic modifications observed in the islets of
12-month-old rats revealed that the differentially expressed
genes were enriched for miR-34a and miR-181a targets.
Indeed, the induction of miR-34a and reduction of miR-181a
in the islets of young animals mimicked the impaired beta cell
proliferation observed in old animals. mRNA coding for alpha-
type platelet-derived growth factor receptor, which is critical
for compensatory beta cell mass expansion, is directly inhibited
by miR34a and is likely to be at least partly responsible for the
effects of this miRNA.
Conclusions/interpretation Changes in the level of specific
miRNAs that occur during ageing affect the proliferative
capacity of beta cells. This might reduce their ability to expand
under conditions of increased insulin demand, favouring the
development of type 2 diabetes.
Keywords Ageing . Apoptosis . Beta cell . Diabetes . Insulin
secretion .MicroRNA . Pancreatic islet . Proliferation
Abbreviations
miRNA MicroRNA
Mobs Median number of miRNA recognition elements
PDGF Platelet-derived growth factor
PDGFRα Platelet-derived growth factor receptor α
qPCR Quantitative real-time PCR
SIRT1 Sirtuin-1
UTR Untranslated region
Introduction
Insulin secretion from pancreatic beta cells plays a central role
in blood glucose homeostasis and metabolism control.
Reduced sensitivity of insulin target tissues and a consequent
rise in insulin demand is normally compensated by expansion
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of beta cells and an increase in their secretory activities.
Failure in this compensatory process results in the release of
insufficient insulin to cover the organism’s needs and the
development of type 2 diabetes [1]. Ageing is a risk factor
for several metabolic diseases, including type 2 diabetes.
Indeed, ageing can affect both insulin secretion and insulin
action, and predisposes to glucose intolerance and diabetes
[2].Moreover, ageing is associatedwith impaired proliferation
and increased sensitivity of beta cells to apoptosis [3], reduc-
ing their capacity to cope with an insulin-resistance state. At
present, the mechanisms underlying these phenomena are not
fully understood, but changes in the expression of genes cod-
ing for key proteins have been reported to be involved in the
age-associated decline of beta cell function.
MicroRNAs (miRNAs) are short non-coding RNAs that
bind to the 3′ untranslated region (UTR) of target mRNAs,
causing translational repression and/or messenger degradation
[4]. During the past decade, several studies have demonstrated
the involvement of miRNAs in the regulation of beta cell func-
tion and survival [5–7]. Although the role of miRNAs in the
regulation of beta cell activities has been investigated in various
conditions, including pregnancy and obesity [8–11], the poten-
tial contribution of these molecules to age-associated beta cell
impairment has not, as yet, been explored.
In this study, we compared the islet miRNA profiles of
3- and 12-month-old rats. Several differentially expressed
miRNAs were identified and their roles in beta cell secretion,
proliferation and survival upon chronic exposure to
proapoptotic conditions were systematically investigated.
Methods
Chemicals Prolactin, IL-1β, exendin-4 and platelet-derived
growth factor (PDGF)-AA were obtained from Sigma-
Aldrich (St Louis, MO, USA). TNF-α was obtained from
Enzo Life Sciences (Lausanne, Switzerland) and IFNγ was
obtained from R&D Systems (Minneapolis, MN, USA).
Animals Wistar rats were from Janvier Laboratories
(Le Genest St Ile, France). All procedures were approved by
the Swiss Veterinary Office and were in accordance with
National Institutes of Health guidelines.
Islet isolation and cell culture Islets were isolated by colla-
genase digestion [12] and cultured in RPMI 1640 medium
(Invitrogen, Carlsbad, CA, USA) [9]. Dissociated islet cells
were obtained by trypsin digestion [8]. Human islets were
received from the Cell Isolation and Transplantation Center
(University of Geneva, Geneva, Switzerland). Dissociated
human islet cells were cultured in CMRL medium
(Invitrogen) [9]. The rat insulin-secreting cell line INS832/13
was cultured as previously described [8].
Profiling of miRNA andmRNARNAwas isolated using the
miRNeasy Kit (Qiagen, Hombrechtikon, Switzerland).
MiRNA expression profiling was carried out using Agilent
Technologies (Santa Clara, CA, USA) miRNA Microarrays
[9]. Profiling of mRNAs was carried out by Arraystar
(Rockville, MD, USA).
Measurement of miRNA and mRNA expression MiRNA
expression was assessed using the miRCURY LNAUniversal
RT miRNA PCR kit (Exiqon, Vedbaek, Denmark).
Measurements of mRNA levels were performed by quantita-
tive real-time PCR (qPCR; Bio-Rad, Reinach, Switzerland)
with custom-designed primers (Microsynth, Balgach,
Switzerland) (see Electronic Supplementary Material [ESM]
Methods). MiRNA expression was normalised to the level of
U6 or miR-7, while mRNA expression was normalised to
18S. The level of selected miRNAs in cadaveric human islets
from 11 normoglycaemic donors, and their association with
age, was assessed in our previously published global miRNA
profiling dataset [13].
Transfection and modulation of miRNA levels INS832/13
cells and primary rat or human dissociated islet cells were
transfected with Lipofectamine 2000 (Invitrogen), either with
RNA oligonucleotide duplexes (Eurogentec, Seraing, Belgium)
corresponding to the sequence of the miRNAs (overexpression)
or with single-stranded miScript miRNA Inhibitors (Qiagen)
that specifically inhibit endogenous miRNAs [9]. A custom-
designed small interfering RNA duplex directed against green
fluorescent protein (Eurogentec) and a miScript reference
miRNA (Qiagen) were used as respective controls.
Insulin secretion The insulin content of and insulin secretion
by dissociated rat islet cells were measured by ELISA [14].
Cell death assessment Rat and human islet cells were incu-
bated with 1 μg/ml Hoechst 33342 (Invitrogen) for 1 min. At
least 103 cells/condition were analysed under fluorescence
microscopy (AxioCam MRc 5, Zeiss, Feldbach, Switzerland)
to score the fraction of cells displaying pycnotic nuclei.
Proliferation assay Cells were cultured on poly-L-lysine-
coated glass coverslips. They were fixed with cold methanol,
permeabilised with 0.5% saponin (Sigma-Aldrich) and
exposed for 1 h to antibodies against Ki67 (1:400) (Abcam,
Cambridge, UK) and insulin (1:10,000) (Millipore, Zug,
Switzerland). Coverslips were then incubated for 1 h with
anti-rabbit Alexa-Fluor-488 and anti-mouse Alexa-Fluor-555
antibodies (Invitrogen). Images were collected on an
AxioVision fluorescence microscope.
Luciferase assay A luciferase reporter construct was generat-
ed by inserting 212 nucleotides of the 3′ UTR sequence of rat
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Pdgfra surrounding the putative binding site of miR-34a
between the XhoI and EcoRI sites of psiCHECK-1 (ESM
Methods). Luciferase activity was measured using a dual-
luciferase reporter assay (Promega, Madison, WI, USA).
Firefly luciferase activity was normalised for transfection
efficiency with the SV40-driven Renilla activity generated
by pGL3-Basic (Promega).
Western blotting Cells were lysed in Laemmli buffer.
Lysates were resolved by SDS-PAGE, transferred to a
PVDF membrane and detected using antibodies against
PDGF receptor α (PDGFRα) (catalogue no. 3174; Cell
Signaling Technology, Danvers, MA, USA) and α-tubulin
(Fluka Chemie, Buchs, Switzerland) [15]. After 1 h incuba-
tion at room temperature with horseradish peroxidase-
conjugated secondary antibodies (Fluka Chemie), membranes
were revealed by chemiluminescence (Immobilon, Millipore)
using the ChemiDoc XRS+ System (Bio-Rad Laboratories).
miRNA target enrichment analysis For each differentially
expressed miRNA, we estimated the median number of
miRNA recognition elements (Mobs) predicted, using
TargetScan (version 6.2) [16], in the 3′UTR (rn6, downloaded
from UCSC [17] on 10 April 2015) of n up- or downregulated
genes. To obtain an empirical p value associated with each
Mobs, we independently estimated 1,000 times the median
TargetScan predicted density of miRNA recognition elements
for N regions of matching length randomly sampled from the
3′ UTRs of rat islet mRNAs that were not differentially
expressed.
Statistical analysis Statistical differences were tested using
Student’s t test or for multiple comparisons, with ANOVA
followed by a post hoc Dunnett test, with a discriminating
p value of 0.05 (SAS statistical package, Cary, NC, USA).
Results
As observed by others [18, 19], 12-month-old male Wistar rats
displayed an increase in body weight but no difference in blood
glucose levels compared with 3-month-old animals (ESM
Fig. 1). In agreement with these observations, insulin content
and glucose-stimulated insulin secretion from islets isolated
from older animals were comparable with those of younger
animals (Fig. 1a, b) and the sensitivity of islet cells to apoptosis
was unchanged (Fig. 1c). However, in contrast to beta cells
from young animals, those isolated from 12-month-old rats
displayed no proliferative response to exendin-4, PDGF or pro-
lactin (Fig. 1d–f).
To determine whether these phenotypic traits were linked
to transcriptomic differences, we used microarray analysis to
compare the global mRNA profiles of the islets isolated from
young and old rats.We detected 632 upregulated and 397 down-
regulated genes (fold change >2.0; nominal p<0.05, n=3) in the
islets of 12-month-old rats (ESM Tables 1, 2; microarray data
are deposited in Gene Expression Omnibus under the accession
code GSE72466). These changes are unlikely to reflect differ-
ences in islet composition, since the islet β-cell content is not
modified in 12-month-old animals [20]. Among the upregulat-
ed mRNAs, pathway analysis revealed an enrichment of genes
involved in insulin secretion, mitogen-activated protein kinase
signalling and MODY (ESM Table 3). Changes in the expres-
sion of selected genes belonging to these pathways were veri-
fied by qPCR (ESM Fig. 2). In particular, we confirmed the
induction of genes involved in insulin secretion (such as the
calcium-channel subunits Cacna1c and Cacna1d) and MODY
(Slc2a2 and Neurod1), and encoding the transcription factor
p53 (Tp53).
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Fig. 1 Insulin secretion, apoptosis and proliferation in islets of aged rats.
(a) Insulin secretion of rat islet cells in response to 2 mmol/l (black bars)
or 20 mmol/l (white bars) glucose. Results are represented as fold change
compared with 2 mmol/l glucose in 3-month-old rats. (b) Insulin content
was normalised to total protein content. (c) Apoptosis was measured in
the islet cells of young (white bars) and aged (black bars) animals treated
with IL-1β (10 ng/ml), IFNγ (300 ng/ml) or with a cytokine (Cyt.) mix
(0.1 ng/ml IL-1β, 10 ng/ml TNF-α and 30 ng/ml IFNγ). *p<0.05 vs
untreated rats of the same age. (d–f) Beta cell proliferation in rat islet
cells of 3- and 12-month-old animals treated with exendin-4 (Ex-4;
100 nmol/l) (d), PDGF-AA (50 ng/ml) (e) or prolactin (PRL; 500 ng/ml)
(f) for 5 days was assessed by staining with anti-Ki67 and anti-insulin
antibodies. Results are means ± SD of at least three independent experi-
ments. *p<0.05 by ANOVA and Dunnett’s post hoc test. Ctrl, control;
mo, month
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MiRNAs are major regulators of gene expression and are
involved in senescence and other age-associated phenomena
[21–23]. To study the potential contribution of these RNAs to
age-associated beta cell dysfunction, we analysed by microar-
ray modifications in the islet miRNA profile of 12-month-old
animals. Out of 307 detected miRNAs, 69 displayed changes
in their expression level (nominal p<0.05) (ESM Table 4;
GSE72466). Changes in the level of all miRNAs displaying
an adjusted p<0.05 were verified by qPCR. We indeed con-
firmed the upregulation of miR-124a and miR-383 and the
downregulation of miR-181a andmiR-130b observed bymicro-
array (Fig. 2a–d). The modifications in the levels of these
miRNAs persisted and were in some cases exacerbated in the
islets of 23-month-old animals (Fig. 2a–d). Interestingly, miR-
124a plays a role in beta cell development [24] and insulin
secretion [25], while miR-383 is differentially expressed in
db/db mice and in mice fed a high-fat diet, two models of type
2 diabetes [9].Wewere unable to detect reproducible changes in
the levels of miR-29b, miR-129-1* (currently annotated
miR-129-1-3p), miR-484 and miR-488 (ESM Fig. 3). Thus,
these miRNAs were not further investigated.
MiR-34a increases in different tissues during ageing
[26, 27] and plays a role in islet cell survival and insulin
secretion [28]. Although they did not reach statistical signifi-
cance, the microarray data suggested a possible increase of
miR-34a, miR-34b and miR-34c in the islets of old animals
(ESM Table 4). Indeed, analysis of miR-34a expression by
qPCR confirmed an upregulation of this miRNA in the islets
of both 12- and 23-month-old rats (Fig. 2e). Islet miR-34a
expression was also positively correlated with age in human
islets from normoglycaemic donors of different ages
(r2=0.58, p=0.007) (Fig. 3a). In contrast, we did not detect
significant (p>0.05) correlations between the levels of the
other differentially expressed miRNAs and the age of islet
donors (data not shown). In this case, the effect of ageing
observed in congenic animals may have been masked by
genetic variations in the human donors or by other confound-
ing factors such as sex or BMI [29].
We then verified whether the observed modifications in
miRNA expression are specific for islet cells. Most of the
selected miRNAs displayed expression profiles in insulin tar-
get tissues (liver, skeletal muscle and adipose tissue) and brain
that differed from those of islets (ESM Table 5). In contrast,
and in line with the literature [26, 27], miR-34a was upregu-
lated in the liver and brain of older rats relative to 3-month-old
rats (Fig. 3b, c).
To investigate the impact of the selected miRNAs on beta
cell activities, islet cells of 3-month-old animals were
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Fig. 2 Islet miRNA expression in rats of different ages. miRNA expres-
sion was measured by qPCR. Results are presented as fold change vs the
level in islets of 3-month-old animals and represent means ± SD; n=5.
*p<0.05 vs 3-month-old mice by ANOVA and Dunnett’s post hoc test.
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Fig. 3 Age-associated changes in miR-34a expression in human islets
and in other rat organs. RNAwas isolated from the islets of human donors
of various ages (a) and from the brain (b) and liver (c) of rats aged 3, 12
and 23 months. (a) The miR-34a level was positively correlated with the
age of human islet donors. miRNA expression was measured using
TaqMan LowDensity Array plates (Life Technologies, Zug, Switzerland)
and a global mean normalisation strategy to control for RNA input. Rel-
ative miR-34a levels were calculated using the mean ΔCt of all 11 sam-
ples and log2 transformed for normality. miR-34a expression in brain (b)
and liver (c) of rats. The data are expressed as fold change vs the level of
expression in 3-month-old rats. (b, c) Data represent means ± SD
*p<0.05 vs 3-month-old rats by ANOVA and Dunnett’s post hoc test.
Mo, month
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transfected with miRNA mimics or anti-miRs to reproduce the
changes in their expression that occur during ageing
(ESM Fig. 4). Modifications in the levels of these miRNAs
did not affect insulin content or insulin secretion (Fig. 4).
Since ageing is characterised by increased susceptibility of beta
cells to apoptotic stimuli [3], we investigated the impact of
these miRNAs on beta cell survival. We found that overexpres-
sion of miR-34a triggers apoptosis of rat (Fig. 5a) and human
islet cells (Fig. 5b). Downregulation of miR-130b and overex-
pression of miR-383 did not affect apoptosis of rat (Fig. 5c, e)
or human (Fig. 5d, f) islet cells, whereas they exerted a protec-
tive effect when the cells were treated with cytokines.
Downregulation of miR-181a or overexpression of miR-124a
modified neither the basal apoptotic rate nor survival in the
presence of cytokines (ESM Fig. 5).
We next assessed the impact of the selectedmiRNAs on beta
cell proliferation. We observed that overexpression of miR-34a
(Fig. 6a, b) or downregulation of miR-181a (Fig. 6c, d) did not
affect basal beta cell proliferation, but did inhibit proliferation
stimulated by exendin-4 or PDGF-AA. In contrast, beta cell
proliferation was unaffected by overexpression of miR-383
and miR-124a or downregulation of miR-130b (Fig. 6e–g).
To unravel the mechanisms underlying the effects of
miR-34a and miR-181a on age-associated beta cell dysfunc-
tion, we searched for potential targets within genes expressed
in the islets of aged animals. Analysis of the protein-coding
genes differentially expressed in islets of 12-month-old rats re-
vealed significant enrichment for potential targets of miR-181a
in the upregulated genes (Fig. 7b, ESMTable 6) and depletion of
predicted targets in the downregulated genes (Fig. 7a, ESM
Table 7). Moreover, the upregulated genes were significantly
depleted from miR-34a targets (Fig. 7d, ESM Table 6) and,
although the values did not reach statistical significance
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content. Dissociated rat islet cells were transfected with oligonucleotides
leading to overexpression (a–c) or downregulation (d, e) of the indicated
miRNAs. Insulin secretion (a–e) and insulin content (f, g) in response to
2 mmol/l (black bars) or 20 mmol/l (white bars) glucose was measured
48 h post transfection. Insulin release is expressed as fold change vs
2mmol/l glucose in the control (ctrl) condition. Data represent means ± SD
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Fig. 5 Impact of changes in miRNA expression on apoptosis. Dispersed
rat (a, c, e) and human (b, d, f) islet cells were transfected with oligonu-
cleotides leading to overexpression (a, b, e, f) or downregulation (c, d) of
the indicated miRNAs. Apoptosis was assessed by scoring the cells
displaying pycnotic nuclei. Incubation of cells transfected with control
(ctrl) oligonucleotides during 24 h with a mix of proinflammatory cyto-
kines (10 ng/ml TNF-α, 0.1 ng/ml IL-1β and 30 ng/ml IFNγ; cyt) was
used as a positive control for apoptosis. Results are the means ± SD of
three or four independent experiments. *p<0.05 (vs control for a, b) by
ANOVA and Dunnett’s post hoc test
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(p<0.071), the downregulated genes tended to be enriched in
the predicted targets of this miRNA (Fig. 7c, ESM Table 7).
These observations suggest that age-associated changes in
miR-181a and miR-34a levels contribute to the gene expression
differences observed in the islets of aged rats.
PDGFRα, a receptor whose decrease contributes to im-
paired age-associated beta cell proliferation [30], is a member
of the beta cell ‘disallowed gene’ family [31]. Western blot
analysis revealed that the levels of this receptor are reduced in
the islets of 12-month-old rats (Fig. 8a). PDGFRα is a predicted
target of miR-34a (www.targetscan.org) and is regulated by this
miRNA in cancer cells [32]. Although Pdgfra expression is
upregulated in islet beta cells after DICER deletion and global
miRNA suppression [33], its targeting by miR-34a in beta cells
has not been explored. To experimentally verify PDGFRα as a
target for miR-34a in these cells, INS832/13 cells were
transfected with a luciferase construct containing the 3′ UTR
of Pdgfra mRNA. Overexpression of miR-34a resulted in
reduced luciferase activity, confirming that Pdgfra is indeed a
direct target of miR-34a (Fig. 8b). Moreover, western blot
analysis of rat islet cells overexpressing miR-34a confirmed
that the miRNA reduces the levels of PDGFRα (Fig. 8c, d).
Discussion
Ageing is a risk factor for the development of type 2 diabetes. In
fact, it is associated with a progressive decrease in insulin sen-
sitivity and a decline in beta cell function [2]. The mechanisms
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Fig. 6 Impact of changes inmiRNA expression on beta cell proliferation.
Rat islet cells were transfected with oligonucleotides leading to overex-
pression (a, b, e, f) or downregulation (c, d, g) of the indicated miRNAs
and treated with exendin-4 (Ex-4; 100 nmol/l) or PDGF-AA (50 ng/ml)
(black bars). Beta cell proliferation was assessed 48 h later by anti-Ki67
and anti-insulin staining. The results represent the means ± SD of three to
six independent experiments. *p<0.05 by ANOVA and Dunnett’s post
hoc test. Ctrl, control
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Fig. 7 Number of miR-34a and miR-181a recognition elements in the 3′
UTR of differentially expressed mRNAs in islets of 12-month-old rats.
The median number of recognition elements (Mobs) for miR-181a (a, b)
and miR-34a (c, d) predicted in the 3′ UTR of all down- (a, c) and
upregulated (b, d) mRNAs in ageing (arrows) was compared with a null
distribution of the median number of predicted recognition elements ob-
tained for 1,000 randomly sampled sets of 3′ UTRs from mRNAs
expressed in rat islets. p is the associated empirical p value and corre-
sponds to the proportion of values in the null distribution that are either
smaller or larger (left and right side of the distribution, respectively) than
Mobs. (a) p=0.025; (b) p=0.023; (c) p=0.071; (d) p=0
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underlying these effects are not fully understood, but are likely
to involve changes in gene expression. Here, we investigated the
transcriptomic modifications occurring in islets of 12-month-old
rats. In agreement with other studies [34], we did not observe
alterations in insulin secretion or apoptosis in the islets of these
animals, suggesting that beta cells preserve the capacity to ac-
complish their basic tasks. However, beta cells from 12-month-
old rats were unable to respond tomitogens. The loss of beta cell
proliferation is probably not a significant handicap under normal
conditions, but might constitute a major obstacle to the achieve-
ment of blood glucose homeostasis under conditions of insulin
resistance requiring compensatory beta cell mass expansion.
Our data indicate that the expression of several protein-
coding genes and miRNAs is already modified in the islets
of 12-month-old rats. Some of these transcriptomic changes
are likely to have a positive impact on beta cell function. For
instance, we detected the upregulation of genes involved in
insulin release, such as those coding for calcium-channel sub-
units [35–37] and the glucose transporter GLUT-2 (Slc2a2)
[38]. These data suggest the existence of compensatory mech-
anisms operating to maintain efficient insulin secretion in
12-month-old animals.
In addition to differences in protein-coding genes, the islets
of 12-month-old rats also displayed modifications in the
miRNA profile. When changes in the levels of selected
miRNAs were reproduced in islet cells of young animals,
none of them affected insulin biosynthesis or secretion. In cell
lines, overexpression of miR-124a and miR-34a has previous-
ly been reported to inhibit insulin secretion [25, 28, 39] but
this observation was not confirmed in another study, although
glucose-induced Ca2+ fluxes were affected bymiR-124a over-
expression [24]. These discrepant findings might be due to
differences in the level of overexpression achieved after cell
transfection. Moreover, because of transcriptomic differences,
these miRNAs might have distinct impacts on insulin secre-
tion in primary beta cells and tumoral beta cell lines. These
miRNAs reduce the expression of key components of the
machinery of insulin exocytosis [25, 28, 39]. Thus, although
overexpression in beta cells of young animals did not signif-
icantly impair insulin release, we cannot exclude the possibil-
ity that the presence of higher levels of miR-34a or miR-124a
would exacerbate the secretory decline of ageing beta cells.
Several of the miRNAs displaying expression changes in
ageing animals affect the survival of beta cells. Indeed, down-
regulation ofmiR-130b or induction of miR-383 improved the
survival of beta cells under proapoptotic conditions. Similar
protective effects have already been reported for other
miRNAs under insulin-resistance conditions [8, 9]. The
changes in the levels of these miRNAs might be sufficient to
compensate for the proapoptotic effect elicited by the concom-
itant upregulation of miR-34a. This suggests that a balance
between the action of proapoptotic and antiapoptotic
miRNAs prevents a net loss of beta cells in 12-month-old rats.
The most striking defect observed in beta cells of
12-month-old rats was the loss of proliferation in response to
mitotic stimuli. Interestingly, overexpression of miR-34a or
blockade of miR-181a was sufficient to reproduce this pheno-
typic trait in the islets of younger animals. The mechanism
through which the downregulation of miR-181a contributes
to the age-associated impairment of beta cell proliferation re-
mains to be established. However, analysis of differentially
expressed genes in the islets of 12-month-old rats revealed
an enrichment of miR-181a targets in the upregulated
mRNAs and a reduction in those that were downregulated.
Thus, attenuation of the repressive activity of this miRNA
appears to contribute to transcriptomic modifications occur-
ring in the islets of ageing animals. The islet gene-expression
profile of ageing animals also appears to be influenced by the
induction of miR-34a. Indeed, the 3′ UTR of the upregulated
genes was depleted from potential recognition sequences for
this miRNA, and the putative miR-34a targets tended to be
more frequent in genes downregulated in ageing. Some of the
targets of miR-34a might be directly involved in the prolifer-
ative defect. Indeed, we demonstrated that the mRNA coding
for PDGFRα is directly targeted by miR-34a. PDGFR
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Fig. 8 PDGFRα is a direct miR-34a target. (a) The levels of PDGFα in
the islets of 3- and 12-month-old rats was determined by western blotting.
The dot blot indicates the values of each of the tested rats (*p<0.05 by
Student’s t test). (b) INS832/13 cells were co-transfected with miR-34a
mimic and with a reporter construct containing the 3′ UTR of PDGFRα.
Luciferase activity wasmeasured 2 days later. The results are expressed in
relative light units (RLU) and are means ± SD (n=3). *p<0.05 vs control
(Ctrl) by Student’s t test. (c, d) Dissociated rat islet cells were transfected
with a control oligonucleotide or with themiR-34amimic. Two days later,
the levels of PDGFRα were analysed by western blotting. The figure
shows a representative blot (c) and band quantification (d) from four
independent experiments. Data are means ± SD. *p<0.05 vs control
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signalling plays a critical role in postnatal beta cell mass
expansion and in beta cell regeneration [30]. Thus, the trans-
lational repression of Pdgfra exerted by the induction of
miR-34a is likely to contribute to the loss of proliferative
capacity observed during ageing.
The increase in the level of miR-34a in the islets of ageing
rats is probably linked to the activation of p53 signalling. Indeed,
we have previously reported that, in insulin-secreting cells, this
transcription factor binds to the promoter of miR-34a and trig-
gers expression of themiRNA [40]. The p53 pathway is induced
by a variety of stresses and plays a pivotal role in cellular senes-
cence and metabolic homeostasis [41, 42]. p53 and miR-34a are
linked in a positive-feedback loop to sirtuin-1 (SIRT1). Indeed,
p53 induces the expression of miR-34a and the miRNA targets
and represses SIRT1, preventing SIRT1-mediated deacetylation
of p53 and, in turn, promoting the activity of the transcription
factor [43]. Consistent with this model, we found that increases
in p53 and miR-34a in the islets of ageing animals were indeed
associated with reduced levels of SIRT1.
In addition to being upregulated in islets, the level of
miR-34a was also elevated in the liver and brain of old rats,
pointing to a general role for this miRNA in the ageing process.
Moreover, the expression of this miRNA has been found to be
abnormally elevated in islets and insulin target tissues of obese
animals [40, 44, 45], contributing to beta cell failure and insulin
resistance. Being at the crossroad between ageing andmetabolic
imbalance, these findings point to miR-34a induction as an im-
portant risk factor for the development of type 2 diabetes. This
will particularly hold true for individuals expressing single
nucleotide polymorphisms within the precursor of miR-34a that
result in increased expression of this miRNA [46].
In this study, we identified a group of islet miRNAs
that display expression changes during ageing and are
likely to contribute to the progressive failure of beta
cells to compensate for insulin resistance. A better un-
derstanding of the role and the mode of action of these
miRNAs in beta cells might open the way to the devel-
opment of new strategies for the prevention and/or treat-
ment of type 2 diabetes.
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